Bivalirudin Bivalirudin Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech "Hirudo medicinalis"). Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide. It is a potent and highly specific inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind
Custom peptide synthesis Custom peptide synthesis Custom peptide synthesis is the commercial production of peptides for use in biochemistry, biology, biotechnology, pharmacology and molecular medicine. Custom peptide synthesis provides synthetic peptides as valuable tools to biomedical laboratories. Synthetic oligopeptides are used extensively in research for structure-function analysis (for example to study protein-protein interfaces), for the development of binding assays, the study of receptor agonist/antagonists or as immunogens for the production of specific antibodies. Generally, peptides are synthesized by coupling the carboxyl group or C-terminus of one amino acid to the amino group or N-terminus of another using automated solid phase peptide synthesis chemistries.